MAP2K7 and cancer: Using a Drosophila model of Ras-driven, polarity-impaired cancer, we undertook a specialised screen of chemical libraries and identified two compounds that showed synergy with sub-therapeutic doses of the MEK inhibitor trametinib, identifying the Polo-like kinase inhibitor volasertib, and the 5-HT2A/2C serotonin receptor and DGKα inhibitor ritanserin.